Expertise in
59
conditions

Dr. Timothy K. Huyck

Hematology | Oncology
Nebraska Cancer Specialists
611 Fenwick Dr, 
Papillion, NE 
Accepting New Patients
21 Years of Experience
Expertise in
59
conditions
Nebraska Cancer Specialists
611 Fenwick Dr, 
Papillion, NE 

Overview

Timothy Huyck is a Hematologist and an Oncologist practicing medicine in Papillion, Nebraska. He has been practicing medicine for over 21 years.

Dr. Huyck is highly rated in 59 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Thrombocytopenia, Pancreatectomy, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 19 clinical trials. Dr. Huyck is currently accepting new patients.

Graduate Institution

CUMC School Of Medicine, 2005

Residency

CUMC School of Medicine, Internal Medicine

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NE

Fellowships

Northwestern University, Hematology/Oncology - 2012

Hospital Affiliations

The Nebraska Methodist Hospital
Chi Health Lakeside
Chi Health Midlands
Chi Health Bergan Mercy
The Nebraska Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 14 Less Insurance Carriers -

Locations

Nebraska Cancer Specialists
611 Fenwick Dr, Papillion, NE 68046

Additional Areas of Focus

Dr. Huyck has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

4 Total Publications

Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.
Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.
Journal: The oncologist
Published: March 29, 2024
Similar Doctors
Expertise in
34
conditions
Dr. Julie M. Vose
Hematology | Oncology
Expertise in
34
conditions
Dr. Julie M. Vose
Hematology | Oncology
Referral may be required

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (3.2 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Julie Vose is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. Dr. Vose is highly rated in 34 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vose is currently accepting new patients.

Expertise in
23
conditions
Dr. Vijaya R. Bhatt
Hematology | Oncology
Expertise in
23
conditions
Dr. Vijaya R. Bhatt
Hematology | Oncology
Referral may be required

Fred & Pamela Buffett Cancer Center - Bellevue Health Center

2510 Bellevue Medical Center Drive, Suite 250, 
Bellevue, NE 
 (9.7 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Vijaya Bhatt is a Hematologist and an Oncologist practicing medicine in Bellevue, Nebraska. Dr. Bhatt is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bhatt is currently accepting new patients.

Expertise in
20
conditions
Dr. James O. Armitage
Hematology | Oncology
Expertise in
20
conditions
Dr. James O. Armitage
Hematology | Oncology
Referral may be required

Fred & Pamela Buffett Cancer Center - Village Pointe Health Center

111 N. 175th St., 
Omaha, NE 
 (7.6 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

James Armitage is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. Dr. Armitage is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Endoscopy. Dr. Armitage is currently accepting new patients.

Frequently Asked Questions about Dr. Timothy K. Huyck

Is Dr. Timothy K. Huyck a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Timothy K. Huyck is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Timothy K. Huyck specialize in?

While Dr. Timothy K. Huyck is a Hematology, they have specific expertise in Colorectal Cancer, Familial Colorectal Cancer, and Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Timothy K. Huyck participate in research or clinical trials?

Yes. Dr. Timothy K. Huyck has published 4 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Timothy K. Huyck's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Timothy K. Huyck accept my insurance?

Dr. Timothy K. Huyck accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Huyck's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 44 Advanced Conditions
    View All 91 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile